From the Annual report:
Thomas C. Drees, Ph.D., MBA, CEO, President and Chairman of the
Board of Directors. Dr. Drees, age 69, is the founder of Sanguine California.
From 1978 to 1984, he was the President and CEO of Alpha Therapeutics
Corporation, a subsidiary of Green Cross Corporation of Japan and the
developer of Fluosol DA 20, the only FDA-approved synthetic blood product.
For 24 years, Dr. Drees has been involved at top management levels with the
collection, manufacture and marketing of human blood plasma derivatives. He
has written many publications on the subject, including the widely-acclaimed
book Blood Plasma: The Promise and the Politics, Ashley Books, New York,1983. |
